Transpara and Mia Cut Mammography Costs by €59,320 per 1,000 Women

A July 2025 Swedish cost-effectiveness study put a number on something procurement teams have been circling for years: AI-assisted mammography saves an estimated €59,320 per 1,000 women screened over a programme’s lifetime, with 10.8 quality-adjusted life years gained, compared with conventional double-reading. For radiology departments running flat headcount against rising scan volumes, that figure moves the conversation from clinical curiosity to budget line.

What the Market Is Buying

The AI mammography market was valued at roughly $160 million in 2025 and is expected to grow substantially by 2035, though no named research firm underpins those projections. The commercial pressure is real regardless: breast cancer remains among the leading causes of cancer mortality globally, and radiologist supply has not kept pace with screening demand.

ScreenPoint Medical‘s Transpara and Kheiron Medical Technologies‘ Mia both address detection accuracy, workflow fit with existing PACS and RIS infrastructure, clinical validation and net cost impact. Their strongest evidence, however, sits in different places.

Transpara: The Workload Case

The headline numbers come from the MASAI trial, a randomised controlled trial run in Sweden with more than 100,000 women, published in 2021. Transpara increased cancer detection by 29% and cut radiologist workload by 44% compared with standard double-reading. That combination is unusual: most detection gains in screening come with workload costs, not reductions. Low-risk cases are left unmarked, giving radiologists a defensible basis for expedited review on a cohort the system assigns a very high negative predictive value.

The July 2025 cost-effectiveness study extended the MASAI findings, estimating that AI-assisted digital mammography reached break-even by the second screening at age 42. Transpara is deployed across more than 30 countries and has processed more than 13 million mammograms. ScreenPoint Medical secured $16 million in funding in April 2026, including non-dilutive research grants, according to reports.

Mia: The Detection Case

Kheiron’s Mia slots into screening workflows as an independent second reader, a concurrent reader, or within a double-reader triage setup. Its strongest evidence is a 2023 prospective study in Nature Medicine: Mia detected up to 13% more breast cancers than human readers alone in a European healthcare setting, with authors suggesting missed cancer rates could be cut by half. The “up to” qualifier matters, actual gains vary by site, patient mix and reader quality, and the framing of the missed-cancer reduction reflects the authors’ interpretation rather than a direct trial outcome.

On cost, a modelling exercise for the UK’s NHS estimated Mia at £4.72 per scan including maintenance, producing a combined read cost of £10.62 when paired with one human radiologist, against £11.80 for two human radiologists. That model was built on pricing provided by Kheiron, so it reflects the company’s own figures rather than independent auditing. Mia is cleared for use in the UK and Europe.

Kheiron also offers Mia IQ, a separate tool that retrospectively reviews mammograms to flag discrepancies in breast positioning and compression. The practical use case is technologist training and compliance with quality standards including the FDA’s Mammography Quality Standards Act EQUIP initiative. As part of the broader push toward FDA-cleared AI tools in breast cancer screening Mia IQ’s positioning puts Kheiron directly in the regulatory compliance conversation for health systems treating image quality as a precondition for AI performance.

Where the Evidence Differs

Transpara’s case rests on an RCT. Mia’s rests on a prospective observational study. Both are credible; they are not equivalent in the hierarchy of clinical evidence, and procurement teams should register that distinction when reading vendor materials. Transpara’s MASAI data covers detection and workload simultaneously in a controlled setting. Mia’s Nature Medicine study covers detection in a real-world European population, a different kind of validity, and arguably more representative of routine deployment conditions.

A systematic review of FDA- and CE-cleared AI systems for mammography screening found that both categories produce non-inferior cancer detection with workload reductions compared to traditional double-reading. That finding supports the general case for AI-assisted screening without establishing either platform as definitively superior. The review’s publication is not named in available materials.

Researchers and regulators have noted that AI development datasets for breast cancer screening have historically skewed toward mammograms from White women, and that performance on patients with dense breast tissue, different ethnicities, or different age profiles can diverge from headline trial results. Neither Transpara nor Mia publishes granular subgroup performance data as a standard part of its commercial materials. The EU AI Act’s requirements on high-risk AI systems which include medical imaging tools, make demographic representation in validation data a compliance requirement for enterprises deploying at scale across diverse populations.

Integration Friction

Both platforms are designed for PACS and RIS integration, and both claim vendor-agnostic deployment. The practical friction is rarely the software handshake. It is organisational readiness: IT infrastructure, radiologist training and the workflow redesign required to act on AI outputs rather than simply receive them. Transpara’s risk-stratification output, elevated, intermediate, low, maps directly onto a triage workflow and represents a concrete process change. Mia’s independent-reader mode requires a clearer policy decision about when AI output overrides or supplements a human read.

Both vendors offer cloud deployment to ease multi-site scaling. For health systems spanning multiple imaging centres, data residency requirements in regulated markets add a governance layer that deserves the same scrutiny as the clinical evidence.

Matching Platform to Programme

Transpara is the stronger fit for high-volume screening programmes where radiologist capacity is the binding constraint. The MASAI evidence directly addresses that problem, and the cost-effectiveness data gives finance teams a workable ROI model. Mia fits programmes where maximising detection, particularly of cancers likely to be missed in standard double-reading, is the primary objective, and where the NHS cost modelling is close enough to local pricing to be useful. Mia IQ adds a quality-assurance angle that is genuinely differentiated where technologist training and MQSA compliance are active concerns.

Both vendors and clinical trial authors have framed AI reading as a triage and assistance function, not a standalone diagnostic. The MASAI trial design and Mia’s prospective study both required continuous human review for complex cases regardless of AI output.